ADBest TREAT Registry for adults with atopic dermatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry gathers data from routine dermatology care using electronic forms completed by physicians and patients. It captures disease characteristics, severity scores, treatment patterns, safety, and patient-reported outcomes over time. The study includes adults starting systemic therapy and uses anonymized identifiers to link visits and questionnaires. Data collection is web-based and patient-friendly, with regular follow-up to track disease course and impact on daily life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>18 years
* Planned initiation of systemic therapy
* Clinically confirmed diagnosis of atopic dermatitis
* Written informed consent after patient education

Exclusion Criteria:

* Patient who do not provide written informed consent
* Patients Younger than 18 years
* Patients without a clinically confirmed diagnosis of atopic dermatitis
* Patients for whom systemic therapy is not planned

Where it's running

• Institute for Health Services Research in Dermatology and Nursing, IVDP; University Medical Center Hamburg-Eppendorf,UKE
  Hamburg, Germany Recruiting

Study contacts

• Study coordinator: Matthias Augustin, Prof.Dr.
• Email: m.augustin@uke.de
• Phone: +4940741055428

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin

  This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.

  Recruiting Replior AB · Grenoble · NCT07909967

• How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis

  This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.

  Recruiting University Hospital Bispebjerg and Frederiksberg · Copenhagen · NCT07807228

• QX-4533 safety study in healthy volunteers and people with moderate-to-severe atopic dermatitis

  This study tests the safety and tolerability of QX-4533, given as a pill, in healthy adults and in patients with moderate-to-severe atopic dermatitis to see how the drug behaves in the body and what side effects may occur.

  Recruiting Phase 1 QuantX Biosciences US Inc. · Shanghai, Shanghai Municipality · NCT07800104

• Tilrekimig for moderate-to-severe eczema in teens and adults

  A 52-week study will test tilrekimig against dupilumab and a placebo to see if it helps people 12 and older with moderate-to-severe atopic dermatitis.

  Recruiting at 31 sites Phase 3 Pfizer · Birmingham, Alabama and 49 other locations · NCT07783425

• TRIV-573 for moderate to severe atopic dermatitis in adults

  This study tests whether TRIV-573 can help adults with moderate to severe atopic dermatitis and checks its safety.

  Recruiting at 17 sites Phase 2 Triveni Bio · Fountain Valley, California and 16 other locations · NCT07782333

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.